Home Tags Trastuzumab deruxtecan

Tag: Trastuzumab deruxtecan

General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

Trastuzumab Deruxtecan Shows Clinically Meaningful Survival Across Multiple HER2 Expressing...

Positive results from the ongoing DESTINY-PanTumor02 phase 2 trial (ClinicalTrials.gov Identifier: NCT04482309) * confirms that trastuzumab deruxtecan ([fam-trastuzumab deruxtecan-nxki in the U.S. only] Enhertu®; Daiichi Sankyo and AstraZeneca) continues to demonstrate clinically meaningful and durable responses, leading to a clinically meaningful survival benefit in previously treated patients across multiple human epidermal growth factor receptor 2 (HER2) expressing advanced solid tumors.

ESMO 2023: ADCs Taking Center Stage

During the annual ESMO 2023 Congress, organized by the European Society for Medical Oncology, held October 20 - 24, 2023 in Madrid, Spain, antibody-drug conjugates or ADCs took center stage, with presentations demonstrating the potential these ADCs show in the rapidly changing treatment landscape for various cancers.

Trastuzumab Deruxtecan Offers an Effective Treatment Option for Patients with Difficult-to-treat...

Trastuzumab deruxtecan (Enhertu®; Daiichi Sankyo and AstraZeneca; previously known as DS-8201a) is an effective treatment option for patients diagnosed with difficult-to-treat HER2-expressing solid tumors.

AACR 2023: Preclinical Data Highlights Stable and Efficacious Low Drug-Load ADCs

Two poster presentations at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida, highlight late-breaking preclinical data from studies with an anti-Nectin-4 ADC and anti-HER2 ADC.

Sacituzumab Govitecan Expected to Become Gilead’s Blockbuster Following Expanded Approval

In early February this year, the U.S. Food and Drug Administration (FDA) approved  sacituzumab govitecan-hziy (Trodelvy®; Gilead Sciences) for the treatment of adult patients with...

Trastuzumab Deruxtecan Demonstrates Clinical Activity in Neoadjuvant Setting in Patients with...

Patients diagnosed with hormone receptor-positive (HR+)/HER2-negative breast cancer frequently experience disease response to neoadjuvant therapy. However, following standard chemotherapy or endocrine therapy, even in combination with CDK4/6...

Trastuzumab Deruxtecan Shows Superior Outcomes Over Chemotherapy-based Regimens in Patients Previously...

Trastuzumab deruxtecan is revolutionizing the treatment paradigm. Compared with capecitabine-based regimens, trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) led to higher response rates and longer survival...

Trastuzumab Deruxtecan: Longer Overall Survival than Trastuzumab Emtansine in HER2-positive Metastatic...

The second-line treatment with trastuzumab deruxtecan (T-DXd; Enhertu®; Daiichi Sankyo and AstraZeneca) leeds to significantly longer overall survival compared with trastuzumab emtansine (T-DM1; Kadcyla®; Genentech/Roche) in...

Gilles Gallant, BPharm, PhD, FOPQ, Receives the 2022 George R. Pettit...

Gilles Gallant, BPharm, Ph.D., FOPQ, Chief Development Officer, at Mythic Therapeutics has received the George R. Pettit Individual Input to the Field Award for 2022.  The award was presented at the 13th World ADC Conference, held in San Diego, CA, during the 9th World ADC Awards Ceremony held on Thursday, September 8, 2022.

US FDA Approves Trastuzumab Deruxtecan for the treatment of HER2-Mutant NSCLC

The United States Food and Drug Administration (FDA) has approved trastuzumab deruxtecan* (Enhertu®; Daiichi Sankyo and AstraZeneca) for the treatment of adult patients with...

X